Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting

• Main Authors: Winfried Alsdorf (Author), Joris Diels (Author), Francesca Ghilotti (Author), Joao Mendes (Author), Teresa Hernando (Author), Patricia Cost (Author), Jordan M Schecter (Author), Nikoletta Lendvai (Author), Nitin Patel (Author), Ana Triguero (Author), Margherita Ursi (Author)
• Format: Book
• Published: Becaris Publishing Limited, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim: The phase III randomized controlled trial (RCT) CARTITUDE-4 (NCT04181827) demonstrated superiority of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) over daratumumab, pomalidomide and dexamethasone (DPd) and pomalidomide, bortezomib and dexamethasone (PVd) for relapsed/refractory multiple myel...